Compare GPOR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | IMNM |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1998 | 2020 |
| Metric | GPOR | IMNM |
|---|---|---|
| Price | $159.15 | $25.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $233.33 | $32.80 |
| AVG Volume (30 Days) | 311.6K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 51.40 |
| EPS | ★ 13.82 | N/A |
| Revenue | ★ $1,422,583,000.00 | $6,941,000.00 |
| Revenue This Year | $18.35 | N/A |
| Revenue Next Year | $6.04 | $1,127.34 |
| P/E Ratio | $11.47 | ★ N/A |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $149.18 | $8.67 |
| 52 Week High | $225.78 | $27.65 |
| Indicator | GPOR | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 72.37 |
| Support Level | $149.18 | $19.28 |
| Resistance Level | $162.64 | $27.14 |
| Average True Range (ATR) | 4.58 | 1.06 |
| MACD | 0.79 | 0.25 |
| Stochastic Oscillator | 60.12 | 87.53 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.